Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men

(2013) Jeppe Skov et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

(2013) Minsuk Kim et al.   NATURE MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuates the Progression of Overt Diabetic Nephropathy in Type 2 Diabetic Patients

(2013) Shigeki Imamura et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

(2013) Jeppe Skov et al.   Endocrine Connections

Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1–7)

(2012) Stella Bernardi et al.   CLINICAL SCIENCE

Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC  Activation in Diabetes

(2012) A. Mima et al.   DIABETES

The Midregional Fragment of Pro-A-Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)

(2012) K. J. J. van Hateren et al.   DIABETES CARE

Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

(2012) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

An overview of the pharmacokinetics, efficacy and safety of liraglutide

(2012) Bruce Bode   DIABETES RESEARCH AND CLINICAL PRACTICE

Ambulatory Tonometric Blood Pressure Measurements in Patients with Diabetes

(2012) Simone Theilade et al.   Diabetes Technology & Therapeutics

Exenatide Reduces Urinary Transforming Growth Factor-ß1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria

(2012) Hong Zhang et al.   KIDNEY & BLOOD PRESSURE RESEARCH

N-Terminal Pro-Atrial Natriuretic Peptide Measurement in Plasma Suggests Covalent Modification

(2011) I. Hunter et al.   CLINICAL CHEMISTRY

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

(2011) Hermann Haller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

(2009) T. Okerson et al.   AMERICAN JOURNAL OF HYPERTENSION

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

(2009) B. Gallwitz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE